Apyx Medical (APYX) Liabilities and Shareholders Equity (2010 - 2026)

Apyx Medical's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $63.0 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 4.76% year-over-year to $63.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $245.4 million (down 2.27% YoY) and the FY2025 annual result came in at $66.8 million, up 3.08% from the prior year.
• Liabilities and Shareholders Equity was $63.0 million for Q1 2026 at Apyx Medical, down from $66.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $79.2 million in Q4 2023 and bottomed at $51.8 million in Q4 2022.
• A 5-year average of $62.0 million and a median of $60.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity dropped 24.66% — and 2023, when it soared 53.05%.
• Apyx Medical's Liabilities and Shareholders Equity stood at $51.8 million in 2022, then surged by 53.05% to $79.2 million in 2023, then declined by 18.17% to $64.8 million in 2024, then gained by 3.08% to $66.8 million in 2025, then declined by 5.71% to $63.0 million in 2026.
• Business Quant data shows APYX's Liabilities and Shareholders Equity at $63.0 million in Q1 2026, $66.8 million in Q4 2025, and $57.4 million in Q3 2025.